Contents Page Section 3: Methods Section Documentation – Questionnaire

| 3.1 Assessment of Eligibility Form | page 2 |
|---------------------------------------|--------|
| 3.2 Patient Consent Form UCLH | page 3 |
| 3.3 Patient Consent Form Bristol | page 4 |
| 3.4 Informed Consent and Demographics | page 5 |

NHS Foundation Trust

3.1 SAFFRON Assessment of Eligibility Form

Assessment of Eligibility

| Study ID | | Date |
|----------|--|------------|
| 1. 9 | SCREENING | |
| 1.1. | Three screening questions asked by treatment team | Yes 🗌 No 🗌 |
| diffic | "Are you having any sexual culties/problems in your intimate relationships?" | Yes 🗌 No 🗌 |
| | "Is this a problem for you?" | Yes 🗌 No 🗌 |
| "Wou | uld you like some help with this?" | Yes 🗌 No 🗌 |
| 1.2. | Had treatment for a gynaecological cancer (cancer of the ovary, womb, cervix or vulva) more than 3 months ago | Yes 🗌 No 🗌 |
| 1.3. | Speaks English | Yes 🗌 No 🗌 |
| 1.4. | Over 18 years old | Yes 🗌 No 🗌 |
| | SFI | |
| 2.1. | FSFI Score | |
| 2.2. | Below or equal to 26? | Yes 🗌 No 🗌 |
| 3. E | EXCLUSION CRITERIA | |
| 3.1. | Currently receiving sexual therapy or psychotherapy | Yes 🗌 No 🗌 |
| 3.2. | Current drug or alcohol abuse problem | Yes 🗌 No 🗌 |

University College London Hospitals

NHS Foundation Trust

3.2 SAFFRON Patient Consent UCLH

Department of Women's Cancer Gynaecological Cancer Research Unit University College London 1st Floor Maple House 149 Tottenham Court Road London, W1T 7NF

Patient Consent Form

Name of Trial: Developing a Stepped Approach to Improving Sexual Function after Gynaecological Cancer: a feasibility study (SAFFRON)

Name of Principal Investigator: Dr Sue Gessler

| 1. | I confirm that I have read and understand the information sheet version 2 dated 02/02/2015 for the above trial. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. | | | |
|-----|--|---------------------|------------|--|
| 2. | I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. | | | |
| 3. | I understand that relevant sections of any of my medical notes and data collected during the trial, may be looked at by appropriate individuals from the PRIMENT Clinical Trials Unit, University College London, the Sponsor (and representatives of the sponsor) and relevant regulatory bodies, or from the institution where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records. | | | |
| 4. | I agree to my GP being informed of | my participation in | this trial | |
| 5. | I agree to take part in the above tria | al. | | |
| Nan | ne of Patient | Date | Signature | |

Name of person taking consent (designated responsible person)

Date

Signature

When completed: Take 4 copies. Original and 1 copy to be kept in medical notes and investigator site file, a copy to be given to the patient. In addition, send 3rd copy to CTU.

Page 4

University Hospitals Bristol NHS

3.3 SAFFRON Patient Consent Bristol

NHS Foundation Trust Department of Women's Cancer Gynaecological Cancer Research Unit University College London 1st Floor Maple House 149 Tottenham Court Road London, W1T 7NF

Patient Consent Form

Name of Trial: Developing a Stepped Approach to Improving Sexual Function after Gynaecological Cancer: a feasibility study (SAFFRON)

Name of Principal Investigator: Dr Sue Gessler

| 1. | I confirm that I have read and understand the information sheet version 2 dated 02/02/2015 for the above trial. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. | |
|----|---|--|
| 2. | I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. | |
| 3. | I understand that relevant sections of any of my medical notes and data collected during the trial, may be looked at by appropriate individuals from the PRIMENT Clinical Trials Unit, University College London, the Sponsor (and representatives of the sponsor) and relevant regulatory bodies, or from the institution where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records. | |
| 4. | I agree to my GP being informed of my participation in this trial | |
| 5. | I agree to take part in the above trial. | |

| Name of Patient | Date | Signature |
|--|------|-----------|
| | | |
| Name of person taking consent (designated responsible person) | Date | Signature |

When completed: Take 4 copies. Original and 1 copy to be kept in medical notes and investigator site file, a copy to be given to the patient. In addition, send 3rd copy to CTU.

| | | Page 5 | |
|-----------|--|-------------------------------|------------------------------|
| | | INFORMED CONSENT AND D | EMOGRAPHICS |
| AF | FRON Site: | Visit date: D D | M M Y Y Y Y Visit: Baseli |
| | Screening ID: | Participant Initials: | |
| | | | |
| 1. II | NFORMED CONSENT | | |
| 1.1. | Date participant signed written of form | D D M M Y Y | Y Y |
| 1.2. | Name of person taking informed | l consent | |
| 1.3. | Date person taking informed cor signed written form | nsent D D M M Y Y | Y Y |
| 2. D | DEMOGRAPHICS | | |
| 2.1. | Date of Birth | D D M M Y Y | / Y Y |
| 2.2. | Age | years | |
| 2.3. | Ethnicity | | |
| | (please tick one) | | |
| | <u>White</u> | <u>Mixed race</u> | Black or Black British |
| | White British | White & Black Caribbean | Caribbean |
| | White Irish | White & Black African | African |
| | White Other | White & Asian | Black Other |
| | | Other mixed background | |
| | <u>Chinese</u> | <u>Asian or Asian British</u> | Other ethnicity |
| | Chinese | Indian | Other (please specify below) |
| | | Bangladeshi | |
| | | Pakistani | |
| o 4 | | Other Asian background | |
| 2.4. | Living Situation | Living alone | |
| | (please tick one) | Living with partner | |



Completed by Completed on M M Y Y Y Print Name Signature

| | Page 6 INFORMED CONSENT AND DEMOGRAPHICS | | | | | | | | | |
|------|---|---|--|--|--|--|--|--|--|--|
| SAF | Screening ID: | Visit date: D D M Y Y Y Visit: Baseline Participant Initials: | | | | | | | | |
| 2.5. | Highest completed level of education (please tick one) | Higher degree Degree A level (or equivalent) HNC/HND (or equivalent) NVQ (or equivalent) GCSE (or equivalent) GCSE (or equivalent) No qualification Other (Please specify): | | | | | | | | |
| 2.6. | Employment status (please tick one) | Full time Part time Unemployed - seeking work Unemployed - not seeking work Home maker Retired On sick leave Student Other (Please specify): | | | | | | | | |

| 3. DISEASE RELATED INFORMATION | |
|---|---------------------------------|
| 3.1. Type of Cancer: | |
| | |
| 3.2. Stage of disease (FIGO) | |
| 2.2. Histolenical time | |
| 3.3. Histological type | |
| | |
| 3.4. Date of primary diagnosis (dd/mm/yy) | / / |
| | |
| 3.5. Disease recurrence | Yes 🗌 No 🗌 |
| | Date (if applicable) (dd/mm/yy) |



Y Y

| Page 7 INFORMED CONSENT AND DEMOGRAPHICS | | | | | | | | |
|---|---|--|--|--|--|--|--|--|
| SAFFRON Site: | Visit date: D D M Y Y Y Y Visit: Baseline | | | | | | | |
| Screening ID: | Participant Initials: | | | | | | | |
| 3.6. Menopausal status at diagnosis | Pre-menopausal | | | | | | | |
| (Menopause = 12 months without a | Post-menopausal | | | | | | | |
| period) | Unknown | | | | | | | |
| | | | | | | | | |
| 3.7 Co-morbidity | Yes 🗌 No 🗌 | | | | | | | |
| If yes, which one | Renal disease | | | | | | | |
| | Cardiac disease | | | | | | | |
| | Respiratory disease | | | | | | | |
| | Rheumatic disease | | | | | | | |
| | Diabetes | | | | | | | |
| | Liver disease | | | | | | | |
| | Other (specify) | | | | | | | |
| 4. TREATMENT RELATED INFORMA | TION | | | | | | | |
| 4.1. Surgery | Yes 🗌 No 🗌 | | | | | | | |
| 4.2. Mode of surgery | | | | | | | | |
| | Laparoscopy | | | | | | | |
| | Vaginal | | | | | | | |
| 4.3. Organs removed | Uterus | | | | | | | |
| | Ovaries/ adnexae | | | | | | | |
| | Pelvic nodes | | | | | | | |
| | Para aortic nodes | | | | | | | |
| | Omentum | | | | | | | |
| | ☐ Vagina | | | | | | | |
| | Vulva | | | | | | | |
| | Other | | | | | | | |
| 4.4. Radiotherapy | Yes 🗌 No 🗌 | | | | | | | |
| 4.5. Mode of radiotherapy | External | | | | | | | |
| | Brachytherapy | | | | | | | |
| | | | | | | | | |

| \frown | Completed by | | (| Com | plete | ed on | 1 | | | | |
|----------------------|--------------|-----------|---|-----|-------|-------|---|---|---|---|---|
| Clinical Trials Unit | Print Name | Signature | | D | D | Μ | Μ | Y | Y | Y | Y |

| | | Boog 9 |
|--|----------------------------------|---|
| | INFOR | Page 8 RMED CONSENT AND DEMOGRAPHICS |
| SAFFRON | Site: | Visit date: D M M Y Y Y Visit: Baseline |
| | Screening ID: | Participant Initials: |
| | | Chemotherapy |
| | | Number of cycles given: |
| | | Hormonal Therpay |
| | | Other (specify) |
| 4.6. Time since pr | imary treatment (dd/mm/yy) | 1 1 |
| 4.7. Date of comp | letion of last treatment | / / |
| (dd/mm/yy) | | |
| 5. ECOG/ WHO | Performance Status | |
| Fully active, no | restrictions on activities | |
| Unable to do s | trenuous activities, but able to | carry out light housework and sedentary activities |
| Able to walk and a state of the state of | nd manage self care, but unabl | e to work. Out of bed more than 50% of waking hours |

Confined to a bed or chair more than 50% of waking hours. Capable of limited self-care

Completely disabled. Totally confined to a bed or chair. Unable to do any self care.

Death

| \frown | Completed by | | (| Com | plete | ed or | | | | | |
|----------|--------------|-----------|---|-----|-------|-------|---|---|---|---|---|
| | Print Name | Signature | | D | D | M | Μ | Y | Y | Y | Y |